Shots:
- Nanobiotix to receive a $20M up front and is eligible to receive ~$220 M as contingent payments and milestones along with royalties on net sales of NBTXR3 in the licensed countries
- LianBio to get exclusive rights to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand
- LianBio supports the expansion of Nanobiotix’s P-III study evaluating NBTXR3 in patients with LA HNSCC by enrolling 100 patients in China. LianBio has contributed to enroll in additional 5 registrational studies conducted by Nanobiotix across multiple tumor indications and therapeutic combinations including immunotherapy
Click here to read full press release/ article | Ref: Nanobiotix | Image: Business Wire
The post Nanobiotix Collaborates with Lianbio to Develop and Commercialize NBTXR3 in China and other Asian Countries first appeared on PharmaShots.
